$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000119312517256035 Filed on August 11, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$1.631M	$718.0K	$2.109M
YoY Change	74.25%	-65.96%	44.75%
Cost Of Revenue			$628.0K
YoY Change			-7.37%
Gross Profit			$1.481M
YoY Change			90.12%
Gross Profit Margin			70.22%
Selling, General & Admin	$2.500M	$2.580M	$1.765M
YoY Change	3.05%	46.18%	-24.96%
% of Gross Profit			119.18%
Research & Development	$5.018M	$5.487M	$3.355M
YoY Change	69.24%	63.55%	1629.38%
% of Gross Profit			226.54%
Depreciation & Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	150.0%
% of Gross Profit			6.75%
Operating Expenses	$7.520M	$8.068M	$4.565M
YoY Change	49.86%	76.74%	41.59%
Operating Profit	-$5.889M	-$7.350M	-$3.450M
YoY Change	44.27%	113.04%	38.55%
Interest Expense	$60.00K	$40.00K	$23.00K
YoY Change	160.87%	73.91%	-68.06%
% of Operating Profit
Other Income/Expense, Net	$113.0K	$102.0K	$9.000K
YoY Change	1514.29%	1033.33%
Pretax Income	-$5.830M	-$7.310M	-$3.520M
YoY Change	40.48%	107.67%	37.5%
Income Tax
% Of Pretax Income
Net Earnings	-$5.834M	-$7.312M	-$3.524M
YoY Change	40.48%	107.49%	37.55%
Net Earnings / Revenue	-357.69%	-1018.38%	-167.09%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.049M	-$5.112M	-$88.00M
COMMON SHARES
Basic Shares Outstanding	21.48M shares	21.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.80M	$46.30M	$6.500M
YoY Change	692.59%	612.31%	-37.5%
Cash & Equivalents	$42.81M	$46.34M	$8.377M
Short-Term Investments
Other Short-Term Assets	$3.000M	$2.500M	$600.0K
YoY Change	650.0%	316.67%	100.0%
Inventory			$213.0K
Prepaid Expenses
Receivables	$635.0K	$539.0K	$658.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$46.42M	$49.35M	$7.966M
YoY Change	612.85%	519.51%	-32.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$610.0K	$626.0K	$1.061M
YoY Change	-39.84%	-41.0%	-10.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$0.00
YoY Change
Total Long-Term Assets	$660.0K	$676.0K	$1.076M
YoY Change	-35.86%	-37.17%	-12.87%
TOTAL ASSETS
Total Short-Term Assets	$46.42M	$49.35M	$7.966M
Total Long-Term Assets	$660.0K	$676.0K	$1.076M
Total Assets	$47.08M	$50.03M	$9.042M
YoY Change	524.33%	453.26%	-30.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$409.0K	$632.0K	$94.00K
YoY Change	701.96%	572.34%	-71.69%
Accrued Expenses	$4.142M	$4.019M	$1.331M
YoY Change	151.18%	201.95%	179.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.100M
YoY Change	-100.0%	-100.0%	0.0%
Long-Term Debt Due	$2.000M	$2.000M
YoY Change
Total Short-Term Liabilities	$6.534M	$6.630M	$2.597M
YoY Change	129.02%	155.29%	25.16%
LONG-TERM LIABILITIES
Long-Term Debt	$1.400M	$1.900M	$0.00
YoY Change
Other Long-Term Liabilities	$171.0K	$189.0K	$8.000K
YoY Change	8450.0%	2262.5%	-89.47%
Total Long-Term Liabilities	$171.0K	$189.0K	$8.000K
YoY Change	8450.0%	2262.5%	-89.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.534M	$6.630M	$2.597M
Total Long-Term Liabilities	$171.0K	$189.0K	$8.000K
Total Liabilities	$8.096M	$8.690M	$2.605M
YoY Change	183.57%	233.59%	21.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$87.21M	-$81.37M	-$23.23M
YoY Change	247.83%	250.25%	96.29%
Common Stock	$219.0K	$215.0K	$108.0K
YoY Change	102.78%	99.07%	38.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.99M	$41.34M	$6.437M
YoY Change
Total Liabilities & Shareholders Equity	$47.08M	$50.03M	$9.042M
YoY Change	524.33%	453.26%	-30.95%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$5.834M	-$7.312M	-$3.524M
YoY Change	40.48%	107.49%	37.55%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	150.0%
Cash From Operating Activities	-$5.660M	-$7.080M	-$2.010M
YoY Change	405.36%	252.24%	-8.22%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$110.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$60.00K	-$110.0K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.200M	-760.0K	-50.00K
YoY Change	-11100.0%	1420.0%	-91.8%
NET CHANGE
Cash From Operating Activities	-5.660M	-7.080M	-2.010M
Cash From Investing Activities	-60.00K	-110.0K	0.000
Cash From Financing Activities	2.200M	-760.0K	-50.00K
Net Change In Cash	-3.520M	-7.950M	-2.060M
YoY Change	208.77%	285.92%	-27.21%
FREE CASH FLOW
Cash From Operating Activities	-$5.660M	-$7.080M	-$2.010M
Capital Expenditures	-$60.00K	-$110.0K	$0.00
Free Cash Flow	-$5.600M	-$6.970M	-$2.010M
YoY Change	400.0%	246.77%	-6.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	5000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21483706	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	24000	USD
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	5000	USD
CY2016Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	759000	USD
CY2017Q2	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	381000	USD
CY2016Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	0	USD
CY2017Q2	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	98000	USD
CY2016Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	133000	USD
	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	57000	USD
	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	0	USD
	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	331000	USD
CY2017Q2	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2017Q2	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	850866	shares
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3909000	USD
	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4019000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	124000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	277000	USD
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	221000	USD
CY2016Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1684000	USD
CY2017Q2	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	2135000	USD
	mgen	Adjustmentsto Additional Paidin Capital Reclassificationof Warrant Liability AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability	51000	USD
CY2017Q2	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	0	USD
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	51000	USD
CY2016Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	167000	USD
CY2017Q2	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	210000	USD
CY2016Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2017Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1007000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	632000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	539000	USD
	us-gaap	Accretion Expense AccretionExpense	83000	USD
	us-gaap	Accretion Expense AccretionExpense	61000	USD
CY2016Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	38000	USD
CY2017Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	15000	USD
CY2017Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	67000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2558000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2697000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5147000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	122494000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1014000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	595000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1014000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12788000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3029000	shares
CY2016Q4	us-gaap	Assets Assets	24760000	USD
CY2017Q2	us-gaap	Assets Assets	50026000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	23877000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	49350000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1280000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21235000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8377000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46335000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-12858000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	24231000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	830428	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	833744	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21483540	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	833744	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21483540	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	215000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4667000	USD
CY2017Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3667000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	14000	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	31000	USD
CY2017Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	19000	USD
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	165000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.88
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.92
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	928000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	883000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M35D
CY2017Q2	us-gaap	Employee Stock Ownership Plan Esop Number Of Allocated Shares EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares	200000	shares
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	51000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	133000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	82000	USD
	us-gaap	Interest Paid InterestPaid	77000	USD
	us-gaap	Interest Paid InterestPaid	82000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1210000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2202000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2581000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5862000	USD
CY2016Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2016Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2017Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	182000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-398000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	738000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	519000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-487000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1007000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-346000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	440000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	268000	USD
CY2016Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	83000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	172000	USD
CY2017Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	64000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	135000	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	9705000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	8690000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24760000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50026000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6885000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6630000	USD
CY2016Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	847000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1764000	USD
CY2017Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	488000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	498000	USD
CY2017Q2	us-gaap	Long Term Debt LongTermDebt	3667000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	667000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2000000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1000000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2820000	USD
CY2017Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1871000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	-5000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38361000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4225000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1131000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8633000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15261000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3524000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7147000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-7312000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14292000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3536000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7171000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7312000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14297000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1076000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	102000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	132000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	4789000	USD
CY2017Q2	us-gaap	Notes Payable NotesPayable	3850000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1969000	USD
CY2017Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1979000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	4565000	USD
	us-gaap	Operating Expenses OperatingExpenses	9023000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	8068000	USD
	us-gaap	Operating Expenses OperatingExpenses	15469000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3450000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6991000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7350000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14289000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1261000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	277000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	404000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	391000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	189000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	81000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	189000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	149000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	148000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1490000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	4009000	USD
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1753000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2476000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40703000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3183000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3323000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	625000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	626000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	76981000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3355000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6821000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5487000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9607000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67076000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81373000	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	268000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	268000	USD
CY2017Q2	us-gaap	Revenue From Grants RevenueFromGrants	230000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	682000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1115000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2032000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	718000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1180000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	84000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1014000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	204000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39156000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-61921000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	41336000	USD
CY2016Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	12000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	24000	USD
CY2017Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	5000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	601667	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	601667	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21409708	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16509719	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001193125-17-256035-index-headers.html	Edgar Link	pending
0001193125-17-256035-index.html	Edgar Link	pending
0001193125-17-256035.txt	Edgar Link	pending
0001193125-17-256035-xbrl.zip	Edgar Link	pending
d361591d10q.htm	Edgar Link	pending
d361591dex101.htm	Edgar Link	pending
d361591dex311.htm	Edgar Link	pending
d361591dex312.htm	Edgar Link	pending
d361591dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20170630.xml	Edgar Link	completed
mgen-20170630.xsd	Edgar Link	pending
mgen-20170630_cal.xml	Edgar Link	unprocessable
mgen-20170630_def.xml	Edgar Link	unprocessable
mgen-20170630_lab.xml	Edgar Link	unprocessable
mgen-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q3 Form 10-Q Financial Statement

#000119312517256035 Filed on August 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q3 Form 10-Q Financial Statement

#000119312517256035 Filed on August 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn